Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR-701 FA versus linezolid in ventilated gram-positive nosocomial pneumonia
2013-004154-22Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Tedizolid phosphate IV with Linezolid IV (2 arms). Primary endpoint: All-cause mortality within 28 days after randomization in the ITT Analysis Set. Started Jan 2014; status: completed.
02
Drugs
tedizolidlinezolid
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2013-004154-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004154-22.